ArticleChinese journal of cancer research = Chung-kuo yen cheng yen chiu2020
Immune checkpoint inhibitors for treatment of advanced gastric or gastroesophageal junction cancer: Current evidence and future perspectives.
Article in Chinese journal of cancer research = Chung-kuo yen cheng yen chiu, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 31 citations in OpenAlex.
- Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.Nature medicine · 2024Trial
- Trial
- PER2 knockdown drives immunotherapy resistance in gastric cancer via metabolic reprogramming of myeloid-derived suppressor cells.Cancer & metabolism · 2026Article
- Deep learning-based radiomics and pathomics for decoding tumor microenvironment and predicting immunotherapy outcomes in gastric cancer.Frontiers in immunology · 2026Review
- Innovative Immunotherapy and Its Transformative Impact on Gastric Adenocarcinoma: A Comprehensive Review of the Disease's Origins, Epidemiology, Classification, Diagnosis, and Treatment Options.ACS pharmacology & translational science · 2025Review
- Unveiling the therapeutic potential of HZQYF: exploring the inhibitory impact of a clinical herbal formula on gastric cancer through network pharmacology and transcript analysis.BMC complementary medicine and therapies · 2025Article
- Applications and challenges of immunotherapy in the management of gastric adenocarcinoma: current status and future perspectives.World journal of surgical oncology · 2025Review
- Immune checkpoint inhibitors or anti-claudin 18.2 antibodies? A network meta-analysis for the optimized first-line therapy of HER2-negative gastric cancer.Therapeutic advances in medical oncology · 2024Article
- Cadherin dysregulation in gastric cancer: insights into gene expression, pathways, and prognosis.Journal of gastrointestinal oncology · 2023Article
- Case Report: A rare synchronous multiple gastric carcinoma achieved progression-free disease through NGS-guided serial treatment.Frontiers in oncology · 2023Article
- [MiR-4772 modulates tumor immune microenvironment by regulating immune- related genes in ovarian cancer].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022Article
- Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma.The oncologist · 2022Article
- Myeloid checkpoints for cancer immunotherapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- Correlation between imaging features on computed tomography and combined positive score of PD-L1 expression in patients with gastric cancer.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- Article
- Assessment of PD-L1 mRNA expression in gastrointestinal tumors and the response to immunotherapy.Frontiers in oncology · 2022Article
- A Novel Classification and Scoring Method Based on Immune-Related Transcription Factor Regulation Patterns in Gastric Cancer.Frontiers in oncology · 2022Article
- Association ofAmerican journal of cancer research · 2022Article
- Relationship Between Programmed Death Ligand 1 Expression and Other Clinicopathological Features in a Large Cohort of Gastric Cancer Patients.Frontiers in immunology · 2022Article
- Novel technologies in cfDNA analysis and potential utility in clinic.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the application of conventional therapies, the prognosis of advanced gastric cancer (GC) or gastroesophageal junction cancer (GEJC) is still poor. In recent years, immune checkpoint inhibitors (ICIs) have reshaped the paradigm of cancer therapy. Emerging evidence support the feasibility of programmed cell death-1 (PD-1) and its ligand (PD-L1) inhibition in chemo-refractory GC/GEJC. Nivolumab and pembrolizumab have initially been approved in Japan and United States, respectively for the third-line treatment of progressive GC or GEJC. In March 2020, nivolumab has also been licensed in China for treating advanced GC/GEJC who received ≥2 lines of systemic therapies. Current studies are moving forward to the first-line application or focusing on combination strategies, though data are insufficient and disputable. In this review, we summarize the recently reported and ongoing clinical trials in ICIs for advanced GC/GEJC. Molecular characteristics and clinical implications of different tumor subtypes are also reviewed. We further discuss the safety profile and biomarkers for predicting the response of ICIs, which has guiding values in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.